Skip to main content

Zoonotic Anticipation and Preparedness Initiative

Objective

Emerging infectious diseases are occurring at increasing frequency in Europe and other regions of the world, having profound impacts on public and/or veterinary health as well as disruptive effects on sector, regional or even global economy. The predominantly zoonotic nature of emerging pathogens calls for a One Health approach uniting the human medical and veterinary fields, dedicated to swiftly controlling upon emergence pathogens both at the source and in the human population. In this project, human and veterinary medical institutions, governmental regulatory agencies, expert academic groups and industrial partners, building on existing EU-funded consortia and initiatives, collaborate in establishing a universal platform for the rapid characterization, design and surge production of vaccines and neutralizing reagents against known as well as novel emerging pathogens, in particular viruses. This platform aims at ensuring a fast track for the development, registration and implementation of innovative control tools immediately after severe outbreak events are detected.
The platform will include the identification and characterization of key protective immunogens and corresponding neutralizing antibodies, based on both in silico and in vitro studies, and supported by in vivo studies that have or will generate knowledge on the pathogenesis and immune-kinetics of ZAPI target viruses in model and target animal species. These animal models will be used to characterize protective or therapeutic efficacy of developed vaccines and neutralizing reagents. In silico B-cell epitope mapping and state-of-the-art immune-structural analyses will further predict key immunogens of target as well as related viruses, and demonstrate potential of immuno-profiling technologies to be applied in the face of emerging virus outbreaks. Multi-specific antibody libraries will be constructed based on the swift generation of a broad range of conventional murine monoclonal antibodies as well as completely defined genetically-engineered humanized antibodies and nanobodies. High Throughput Sequencing assays will be developed to efficiently characterize the neutralization capacity of these antibodies within the framework of an automated workflow. Upon an incursion of a novel virus, tailor-made HTS assays will be developed to screen the established antibody libraries for virus neutralizing activity, and to identify B cells from infected individuals, that produce neutralizing antibodies. In both cases, the sequences of these antibodies will be determined to develop recombinant antibodies using systems suitable for rapid, large-scale production. The most promising and potent immunogens and neutralizing reagents will be fed into a universal platform, independent of mammalian cell cultures, for rapid and high-yield production.
Because a unique expression and production system leading to vaccine and/or neutralizing reagent production is unlikely to be successful for the full range of newly emerging viruses in the future, it is essential to develop a universal platform relying on complementary expression and production systems, to be used according to a built-in decision-tree. We therefore include several options within the development pipeline to avoid shortcomings associated with a particular expression or production system. Key immunogens will be either expressed as purified subunits preferably in prokaryotic, fungal or insect cells, or be expressed from the genome of DNA-launched RNA virus replicons. Their immunogenicity will be screened in small-animal models. Selected candidates will further be tested for immunogenicity and efficacy in small animal models and target animal species. At least two expression systems will be validated at medium production scale. Classical benchmark vaccines, produced by existing mammalian or avian cell-based systems, will be used as positive controls in vaccination-challenge experiments. Key neutralizing antibodies will be engin

Call for proposal

IMI-JU-11-2013
See other projects for this call

Coordinator

MERIAL SAS
Address
Avenue Tony Garnier 29
69007 Lyon
France
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Principal investigator
Jean-Christophe Audonnet (Dr)
Administrative Contact
Jean-Christophe Audonnet (Dr)

Participants (19)

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 962 735
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Frank Deege (Mr)
UNIVERSITEIT UTRECHT
Netherlands
EU contribution
€ 794 305
Address
Heidelberglaan 8
3584 CS Utrecht
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Louise van der Kaaden (Dr)
STICHTING WAGENINGEN RESEARCH
Netherlands
EU contribution
€ 1 390 269
Address
Droevendaalsesteeg 4
6708 PB Wageningen
Activity type
Research Organisations
Administrative Contact
Rieske Troost (Mrs)
FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT
Germany
EU contribution
€ 1 210 350
Address
Sudufer 10
17493 Greifswald-insel Riems
Activity type
Research Organisations
Administrative Contact
Dietmar Nobis (Mr)
UNIVERSITATSKLINIKUM BONN
Germany
EU contribution
€ 194 400
Address
Venusberg-campus 1
53127 Bonn
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Beate Becker (Ms)
VIROCLINICS BIOSCIENCES BV
Netherlands
EU contribution
€ 360 000
Address
Marconistraat 16
3029 AK Rotterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Bob Van Gemen (Dr)
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Spain
EU contribution
€ 394 917
Address
Calle Serrano 117
28006 Madrid
Activity type
Research Organisations
Administrative Contact
Ana Maria De La Fuente (Ms.)
INSTITUT PASTEUR
France
EU contribution
€ 192 600
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
Activity type
Research Organisations
Administrative Contact
David Itier (Mr)
UNIVERSITE D'AIX MARSEILLE
France
EU contribution
€ 195 570
Address
Boulevard Charles Livon 58
13284 Marseille
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Céline Damon (Ms)
ARTEMIS BIO-SUPPORT B.V.
Netherlands
EU contribution
€ 766 425
Address
Molengraaffsingel 10
2629 JD Delft
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Eric Claasen (Prof.)
INSTITUT DE RECERCA I TECNOLOGIA AGROALIMENTARIES
Spain
EU contribution
€ 718 467
Address
Ctra C-59 Km 12 Torre Marimon
08140 Caldes De Montbui Barcelona
Activity type
Other
Administrative Contact
Cristina González (Head of the Project Operations Department)
STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER
Germany
EU contribution
€ 747 000
Address
Bunteweg 2
30559 Hannover
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Peter Joppe (Mr)
ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE (IABS-EU)C
France
EU contribution
€ 318 800
Address
World Trade Center - Bd Vivier Merle
69393 Cdx 02 Lyon
Administrative Contact
Joris Vandeputte (Dr)
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 715 500
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jaco de Graaf (Mr)
BOEHRINGER INGELHEIM VETMEDICA GMBH
Germany
Address
Binger Strasse 173
55218 Ingelheim
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Randolph Seidler (Dr)
DYADIC NEDERLAND BV
Netherlands
EU contribution
€ 403 650
Address
Nieuwe Kanaal 7 S
6709 PA Wageningen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Willem Van der Wilden (Dr.ir.)
ASTRAZENECA AB
Sweden
Address
Vastra Maelarhamnen
151 85 Sodertaelje
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Henrik Landström (Mr)
HARBOUR ANTIBODIES BV
Netherlands
EU contribution
€ 173 700
Address
Stationsplein 45, A4.004
3013 AK Rotterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
MariaRiet Van Zeijl (Mrs.)
FINOVATIS
France
Address
Cours Lafayette 68
69003 Lyon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
David Koubi (Dr.)